

Effect of psychatrc medicine on oral cavity – A pharmacologist review

¹Deepak Narang, Reader, Department of Oral Medicine and Radiology, Deshbhagat Dental College, Punjab, India.

²Pallavi Sharma, MD Pshyciatry

³Pooja Gulati, Prof & P.G Guide department of pharmacology, Deshbhagat University Mandigobindgarh, Punjab.

⁴Amandeep Singh, Amandeep Singh, Prof & Head Department of Community Dentistry, Deshbhagat Dental College, Deshbhagat University Mandigobindgarh, Punjab.

⁵Gursandeep Kaur Sandhu, Reader Conservative Dentistry Endodontics Deshbhagat Dental College, Deshbhagat University Mandigobindgarh, Punjab.

Corresponding Author: Deepak Narang, Reader, Department of Oral Medicine and Radiology, Deshbhagat Dental College, Punjab, India.

How to citation this article: Deepak Narang, Pallavi Sharma, Pooja Gulati, Amandeep Singh, Gursandeep Kaur Sandhu, “Effect of psychatrc medicine on oral cavity – A pharmacologist review”, IJMACR- May - June - 2022, Vol – 5, Issue - 3, P. No. 155– 159.

Copyright: © 2022, Deepak Narang, et al. This is an open access journal and article distributed under the terms of the creative commons attribution noncommercial License 4.0. Which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Type of Publication: Review Article

Conflicts of Interest: Nil

Abstract

The aim of the present paper aims to achieve a brief presentation of the oral health problems derived from the long-term administration of the psychotropic medication, in order to emphasize the importance of educating the population and the health specialists how to prevent the oral pathology that can lead to various disabilities, further reducing the quality of life of the patient with mental disorders with chronic evolution. Material and methods The article is structured as a synthesis of recent literature, published in prestigious magazines.

Psychotropic drugs have oral adverse effects such as xerostomia and bruxism. They may also interact with sympathomimetic vasoconstrictors or other drugs used in dentistry but some of these interactions have been overstated. The conscious sedation techniques used by

dentists to manage anxiety require caution and must be used in accordance with treatment guidelines.

Keywords: bruxism, conscious sedation, vaso constrictors, xerostomia.

Introduction

Dental patients may be prescribed psychotropic drugs either for a mental illness (see Table 1) or to manage severe anxiety associated with dental procedures. When psychotropic drugs are used to treat a mental illness, they can cause problems such as xerostomia which need preventive dental care. Taking a medication history is essential for the safe prescribing of dental drugs for concomitant administration. Particular care is needed if the dentist intends to use sedation in a patient who is anxious about dental treatment. adverse effects of

psychotropic drugs may cause dental problems are as follows.

Xerostomia

The most frequently encountered adverse effect of dental importance in patients taking psychotropic drugs is xerostomia. The patient has a perception of dry mouth and the lack of saliva can lead to dental caries and candidosis.[1]

Most antidepressants can cause xerostomia. Drugs with significant anticholinergic activity such as the tricyclic antidepressants are more likely to lead to oral complications, as the effect on salivary function is often prolonged. Newer antidepressants such as venlafaxine, reboxetine and the selective serotonin reuptake inhibitors (SSRIs) can cause dry mouth, but this is likely to be mild and transient, as would often be the case with the psychostimulants.

Other drugs with anticholinergic properties such as antipsychotic drugs and antiparkinsonian drugs used to treat antipsychotic-induced movement disorders may also cause dry mouth. Patients complaining of a dry mouth while taking lithium may be suffering from dehydration as a result of lithium-induced polyuria. They should be referred for appropriate investigation.[2]

If a change to the patient's treatment is not possible, options for the long-term management of xerostomia include dietary modification, saliva substitutes, regular sipping of water and non-pharmacological salivary flow stimulators such as sugarless chewing gum. Sialogogues such as the cholinergic agonist pilocarpine (as diluted eye drops administered topically in the mouth) can be particularly useful for short-term use, but their utility may be limited by systemic adverse effects such as headache, sweating and diarrhoea.[3] Dental management of a patient with xerostomia requires

increased dental recalls for oral hygiene instruction, fluoride application and early intervention.

Table 1: drugs used in psychiatry

Therapeutic group	Common drugs
Anti-depressants	Selective serotonin reuptake inhibitors – including citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline Tricyclic antidepressants – including amitriptyline, dothiepin, doxepin, imipramine, nortriptyline Monoamine oxidase inhibitors – including moclobemide*, phenelzine, tranylcypromine Others – including mianserin, mirtazapine, reboxetine, venlafaxine
Anti-psychotics	Typical (older type) antipsychotics – including chlorpromazine, flupenthixol, fluphenazine, haloperidol, pericyazine, trifluoperazine, zuclopenthixol Atypical (newer type) antipsychotics – including amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone
Sedatives	Benzodiazepines – including alprazolam, bromazepam, clonazepam, diazepam, flunitrazepam, nitrazepam, oxazepam, temazepam, triazolam

	Beta blockers (used for somatic complaints in anxiety disorders) – particularly propranolol
Psychostimulants	Including atomoxetine, dexamphetamine, methylphenidate
Drugs for bipolar disorders	Including carbamazepine, lamotrigine, lithium, sodium valproate
Anti-parkinson's drugs	Benztropine

Bruxism

Bruxism involves forceful excursive movements of the jaw with grinding of the teeth and leads to excessive dental attrition with various complications. It is occasionally seen with antipsychotics, anti-depressants and psychostimulants though it is rarely prolonged. Bruxism may also occur independently of medication in patients suffering symptoms of anxiety associated with mental illness. The complications of persistent bruxism can be reduced by the use of an occlusal splint.

Surgical bleeding

Sodium valproate, an anticonvulsant used in patients with bipolar disorders, is associated with a relatively high incidence of thrombocytopenia and it impairs platelet aggregation. It has been reported to potentiate surgical bleeding and this may occur in dental patients. It may be prudent to obtain relevant laboratory investigations such as platelet count and function before dental surgery.

If a significantly abnormal result is obtained the patient should be referred to their medical practitioner for appropriate management. Some antidepressants, in particular the SSRIs, also impair platelet aggregation due to their effects on platelet serotonin uptake. Compared to

valproate, less is known about their effect on surgical bleeding, but some caution may be required.[2]

Drug-induced excess salivation

The atypical antipsychotic clozapine has many adverse effects, including cholinergic agonism which leads to hypersalivation –often nocturnal, but sometimes continual – in a large proportion of patients. During dental treatment, excess saliva may compromise dental materials, create a difficult working environment for the dentist and pose a risk of aspiration.

Anticholinergic drugs are commonly used for patients suffering clozapine-induced hypersalivation. Hyoscine hydrobromide 300 micrograms chewed and swallowed before dental work, in addition to standard measures for maintaining a dry field, may be helpful.[4]

Operative use of vasoconstrictors

Sympathomimetic vasoconstrictors such as adrenaline, used in conjunction with local anaesthetics to prolong anaesthetic effect and control local bleeding, are generally safe, but there are some interactions with prescribed psychotropic drugs. [5] These would be most significant following inadvertent intravenous administration of the vaso constrictor. Much has been made in the literature of the potential for interaction between local sympathomimetic vasoconstrictors and tricyclic antidepressants, but this is probably most significant with levonordefrine and with noradrenaline (neither in common use in Australia).

The antidepressants may potentiate the action of adrenaline and possibly increase the patient's blood pressure. If adrenaline is necessary, consider using about one-third of the normal amount. Some conjecture exists about the potential for an interaction between monoamine oxidase inhibitors and dental sympathomimetic vasoconstrictors to cause severe

hypertensive reactions. Insufficient evidence has been produced to substantiate this interaction and the combination would generally be regarded as safe. It has also been claimed that some antipsychotics can adversely interact with sympathomimetic vasoconstrictors through their alpha blocking activity.

The consequent unopposed beta activity of the sympathomimetic might lead to peripheral vasodilation resulting in prolonged bleeding, hypotension, and reflex tachycardia. The evidence in dental practice has not borne this out sufficiently to warrant serious concern where adrenaline is used for its local effect.⁵ Interactions can occur when patients taking non-selective beta blockers are given local anaesthetics containing adrenaline. A lower dose is advised with extra care to avoid intravascular injection.^[5]

If there is concern about interactions with sympathomimetic vasoconstrictors, felypressin may be an alternative. Interactions have not been reported with this non-sympathomimetic vasoconstrictor.

Post-operative prescribing

Patients who need pain relief after dental treatment should not be denied analgesia because they are taking psychotropic drugs. There are important interactions and some combinations should not be used. For example, dextropropoxyphene should not be used in combination with carbamazepine or monoamine oxidase inhibitors, and tramadol or pethidine should generally not be used in combination with antidepressants due to the risk of serotonin syndrome. Alternatives are usually available and paracetamol with codeine is often effective.

Patient participation in preventive dentistry

Patients with a mental illness may be less likely than others to follow oral hygiene advice but can do so if carefully instructed.^[3] Close liaison with other health

professionals involved in the patient's general medical and psychiatric management may result in more favorable outcomes

Pharmacological management of the anxious dental patient

Anyone may suffer anxiety of a severity necessitating pharmacological management in order to facilitate dental treatment. Benzodiazepines and nitrous oxide are the most frequently used drugs. When considering the use of conscious sedation, the 'Guidelines on conscious sedation for dental procedures'⁷ should be referred to and all appropriate safety measures taken.

Benzodiazepines

Benzodiazepines alleviate anxiety, and cause sedation, anterograde amnesia and muscle relaxation. effects may be of value in treating the anxious patient. These drugs have a wide margin of safety in most patients and differ from one another clinically mainly in their onset and duration of action. Of the oral benzodiazepines, a reasonable choice is temazepam due to its moderate duration of activity and lower propensity for drug interactions. Benzodiazepines should be used with caution in patients taking other central nervous system depressant drugs.

Drug interactions may also increase or decrease effects of benzodiazepines in patients taking other medication. Benzodiazepines should be avoided in pregnancy wherever possible.^{2,8} Patients who have taken a benzodiazepine should be escorted after treatment and advised not to drive or undertake any other potentially hazardous activities for the rest of the day, even if the benzodiazepine has a short half-life. The duration of action of any benzodiazepine can vary from patient to patient. Each of these

Nitrous oxide

Nitrous oxide is a useful and inexpensive inhaled sedative with which many dentists are familiar. It is relatively safe to use provided that appropriate monitoring and procedures for initiation and termination of sedation are followed. Its various advantages include a lack of propensity for drug interactions and rapid 'on-off' activity. If nitrous oxide is being considered for a pregnant patient consult the patient's obstetrician, although it is considered relatively safe with short-term use. Some respiratory illnesses warrant caution, but most other medical conditions pose little problem. It has good anxiolytic and analgesic properties. Adverse effects are uncommon when lower concentrations and shorter durations are used. Nausea and vomiting are occasional problems during recovery. Many patients recover quickly enough to be able to drive home after a short period of observation.

Conclusion

The patients encountered in dental practice are increasingly likely to be taking psychotropic medication due to increased recognition of mental illnesses in the community. It is therefore important for dentists to be familiar with the oral health implications of these drugs. Additionally, dentists frequently use conscious sedation as a useful means of managing the anxious patient and should be well versed in the appropriate use of sedation techniques to ensure safe and effective treatment. Brief psychomotor evaluation tests may be useful in assessing the patient's ability to leave the practice unescorted.[8]

References

1. Olver IN. Xerostomia: a common adverse effect of drugs and radiation. *Aust Prescr* 2006; 29:97-8.
2. Australian Medicines Handbook 2007. Adelaide: Australian Medicines Handbook Pty Ltd; 2007.

3. Little JW, Falace DA, Miller CS, Rhodus NL. Dental management of the medically compromised patient. 6th ed. St Louis, MO: Mosby; 2002.
4. Davydov L, Botts SR. Clozapine-induced hypersalivation. *Ann Pharmacother* 2000; 34:662-5.
5. Yagi Ela JA. Adverse drug interactions in dental practice: interactions associated with vasoconstrictors. *J Am Dent Assoc* 1999; 130:701-9.
6. Therapeutic Guidelines: Oral and Dental. Melbourne: Therapeutic Guidelines Limited; 2007.
7. Guidelines on conscious sedation for dental procedures. Australian and New Zealand College of Anesthetists and the Royal Australasian College of Dental Surgeons. http://www.ada.org.au/app/cmslib/media/lib/0703/m52386_v1_consedps21_2003.pdf [cited 2007 Jul 10]
8. Malamed SF. Sedation: a guide to patient management. 4th ed. St Louis, MO: Mosby; 2003.